Search…

BioAn Biopharmaceuticals (06955.HK): All patients have been enrolled in Phase III clinical trials of Nivolumab in China.

31/10/2025

Zhijong Finance APP News, Boren Biotechnology (06955.HK) announced that the company's self-developed BA1104 (Nivolumab Injection) has completed all patient enrollment in Phase III clinical trials in China. BA1104 is leading the development progress and is the first domestic biosimilar to conduct Phase III clinical trials for Opdivo.

Latest

2 m ago

Digital infrastructure group Equinix announced on Thursday that it plans to invest 3.9 billion to build a new artificial intelligence data center near London, to help boost the development of the AI field in the UK.

3 m ago

Yonyou Network (600588.SH) announces its performance for the first three quarters, with a net loss attributable to shareholders of 1.398 billion yuan.

3 m ago

Heihe Holdings Group (000417.SZ) released its performance for the first three quarters, with a net profit attributable to the shareholders of 172 million yuan, a year-on-year decrease of 17.48%.

5 m ago

Baotong Energy (001376.SZ) released its performance for the first three quarters, with a net profit attributable to the parent company of 132 million yuan, a decrease of 11.23%.

8 m ago

Quanxin Hao (000007.SZ) released its performance for the first three quarters, with a net profit attributable to the parent company of 3.418 million yuan, an increase of 7.62% year-on-year.

See all latest